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ABSTRACT
Breast cancer develops from epithelial lesions in breast ducts and lobules that become invasive and can be metastatic. Breast cancer is a disease of uncontrolled cell division. Cell division normally creates two genetically identical daughter cells through severing of a cytoplasmic bridge that interconnects them. The midbody is an organelle involved in severing. Previously midbodies were thought to be lost from cells after division, but we show they can be retained. is an organelle involved in severing the cytoplasmic bridge. Previously, midbodies were thought to be lost from cells after division, but we show they can be retained, accumulated and increased with tumor grade (Fig. 2-6 ). The long-term goal of this project is to identify putative MB-containing breast cancer cells and target them for chemotherapeutic elimination of breast cancer. We will determine if MBs are present in putative breast cancer stem cells (CSCs) from multiple breast cancer cell lines and tumor types ( Task . Using this method, we showed that there are more MB-positive cells in the breast cancer stem cell population (CD44+, CD24/-low) than in the cell population that was also flow sorted but were MB-negative control (83.1+/-2.1% versus 8.1+/-0.1% for control, ~8-fold greater).
c. We showed that breast cancer stem cells from another breast cancer cell line (MDA-MB-231) isolated by cell surface markers (CD44/CD22-) were enriched in MB-positive cells (61.1+/-0.7% versus 15.0+/-0.2%, ~4-fold). Taken together, these data provide strong evidence that breast cancer stem cells are MB-positive using two methods of isolation, 1) collecting the "side population", 2) collecting cells using stem cell surface markers and 3) by showing they are in multiple different cell breast cancer cell lines.
d. We tested whether breast tumors were enriched in MBs (as in HeLa xenographs, Fig. 5 ) using immunohistochemical and immunofluorescence staining of mouse and human tumors and adjacent nontumor (control) tissue. We found that 67.3+/-3.1% of cells in in breast tumors were MB-positive. In contrast, only 4.5+/-0.01% of cells in adjacent breast tumor tissue, representing more than a 10-fold increase in MB+ cells in tumors.
e. In the course of this study, we made an important and unanticipated discovery that may provide a new and highly innovative opportunity for breast cancer therapies. We identified a large number (n=29) of canonical breast cancer oncogenes and tumor suppressors localized to the MB using both immunofluorescence and biochemical approaches (Fig. 12) . These include breast cancer specific proteins as well as proteins that are associated with many cancers (examples: BRCA1, BRCA2, p53, ErB2, Akt, Cdh1, Fig. 12 ). This new unexpected result may provide a molecular mechanism for the tumorigenic phenotype of MBs and could serve as a novel therapeutic method for treating breast cancer, a) namely targeting post-mitotic MBs for autophagic degradation and b) displacing MB-bound breast cancer associated proteins.
Task 2. Test the tumorigenic potential of MBs.
A Using fluorescence-activated cell sorting, we isolated for MB-positive cells after labeling MBs with the MB marker, GFP-MKLP1 (also with other MB proteins such as CEP55, MgcRacGAP). These MB+ cells showed an increase in soft agar growth and multicellular breast cancer spheroid formation (Fig. 8) . 100-200 cells were capable of making breast tumor spheroids in vitro compared to MB-low controls.
b. The isolated MB+ population of cells also had more tumor-like potential than the MB-negative population (MB+: 41.9+/-2.2, MB-: 7.1+/-0.5% soft agar colonies, Fig. 8 ). This provides additional evidence that MB-positive cells identify the breast cancer stem cell subpopulation of cancer cells. This suggests that MB-positivity could be exploited to isolate breast cancer stem cells from breast cancer cell lines and human breast tumors (i.e. MBs may have potential as markers for breast cancer stem cells). We have had difficulty with tumor growth in mice, but we now believe increasing cell numbers will allow us to complete this work.
c. Test if NBR1 shRNA increases MB+ cells and growth in soft agar. We show that NBR1 depletion blocks autophagic degradation of MBs (see Fig. 9 ) and increases the tumor-like properties of breast cancer cells (Fig. 8) .
Task 3. Test if specific targeting of MBs for autophagic degradation is a therapeutic strategy for breast cancer. a. Test if autophagic degradation of MBs by expression of GFP-NBR1 inhibits soft agar growth.
We showed that NBR1 expression and the resulting decrease in MB+ cells decreases in vitro tumor potential (soft agar growth, Fig. 10A ). b. We identified another member of the NBR1 MB-autophagy pathway by isolating NBR1 binding protein, NipSnip2. This new member of the MB autophagy pathway dramatically increases MB degradation when expressed, leading to decreased tumor-like properties of breast cancer cells. It is more efficacious than NBR1 in this regard (Fig. 10B ). 
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2012:
CONCLUSION:
The results reported in this funding period are very exciting to me, as I am primarily a basic cancer researcher who now has the potential to move into anti-breast cancer strategies. My laboratory has established a new paradigm for breast cancer treatment through the exploitation of a midbody-selective autophagy pathway that eliminates post-mitotic midbodies and kills breast cancer cells. To our knowledge, no other lab is working in this area of cancer biology.
Based on the role of MBs in breast cancer and other progress we have made in this regard, we feel we can take our work to a new level that involves breast cancer therapeutics. We believe that this research will have a sustained and significant impact on breast cancer for a number of additional reasons: The work provides a new understanding of breast cancer etiology, namely a novel role for MBs in maintaining the properties of breast cancer cells. We also believe that we have identified a new and effective breast cancer stem cell identification strategy based on novel and atypical biomarkers, MBs. This study could lead to important "clinical products/outcomes" such as novel breast cancer therapies (targeting MBs), and increased understanding of the etiology of breast cancer (modulation by MBs) and new scaffolds/modulators of breast cancer oncogenes and tumor suppressors (MBs).
